193 related articles for article (PubMed ID: 8962277)
1. Monoclonal antibodies in organ transplantation.
Valdés RH
Transplant Proc; 1996 Dec; 28(6):3293. PubMed ID: 8962277
[No Abstract] [Full Text] [Related]
2. Use of CD3 antibodies in transplantation and autoimmune diseases.
Chatenoud L
Transplant Proc; 1994 Dec; 26(6):3191-3. PubMed ID: 7998111
[No Abstract] [Full Text] [Related]
3. Selective immunosuppression with anti-T cell monoclonal antibodies.
Chatenoud L; Bach JF
Clin Nephrol; 1992; 38 Suppl 1():S53-60. PubMed ID: 1295709
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD3 antibodies.
Chatenoud L; Bach JF
Immunol Ser; 1993; 59():175-91. PubMed ID: 8461387
[No Abstract] [Full Text] [Related]
5. New insights into therapy with monoclonal antibodies in allograft transplantation.
Schena FP
Nephrol Dial Transplant; 1997; 12 Suppl 1():55-8. PubMed ID: 9075230
[No Abstract] [Full Text] [Related]
6. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3.
Sasaki AW; Lee RG; Porayko MK; Benner KG; Hennell KR; Wheeler LJ; Pinson CW
Transplantation; 1993 Jan; 55(1):216-9. PubMed ID: 8420054
[No Abstract] [Full Text] [Related]
7. Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies.
Colvin RB; Preffer FI
Clin Lab Med; 1991 Sep; 11(3):693-714. PubMed ID: 1934971
[TBL] [Abstract][Full Text] [Related]
8. Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.
Lazarovits AI; Rochon J; Banks L; Hollomby DJ; Muirhead N; Jevnikar AM; White MJ; Amlot PL; Beauregard-Zollinger L; Stiller CR
Transplant Proc; 1993 Feb; 25(1 Pt 1):820-2. PubMed ID: 7679844
[No Abstract] [Full Text] [Related]
9. Review and preview of anti-T-cell antibodies.
Helderman JH
Transplant Proc; 1995 Oct; 27(5 Suppl 1):8-9. PubMed ID: 7482824
[No Abstract] [Full Text] [Related]
10. Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation.
Goldstein G
Transplant Proc; 1987 Apr; 19(2 Suppl 1):1-6. PubMed ID: 3105134
[No Abstract] [Full Text] [Related]
11. [Muromonab CD3].
Akioka Y; Hattori M; Ito K
Nihon Rinsho; 2005 May; 63 Suppl 5():747-50. PubMed ID: 15954439
[No Abstract] [Full Text] [Related]
12. CD3 antigen modulation in T-lymphocytes during OKT3 treatment.
Magnussen K; Klug B; Møller B
Transplant Proc; 1994 Jun; 26(3):1731. PubMed ID: 8030108
[No Abstract] [Full Text] [Related]
13. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
[TBL] [Abstract][Full Text] [Related]
14. Orthoclone OKT3 and cardiac transplantation: an overview.
Mahon PM
Crit Care Nurse; 1991 Sep; 11(8):42-7, 50. PubMed ID: 1909947
[No Abstract] [Full Text] [Related]
15. Preventing the rejection of grafted human fetal pancreas.
Tuch BE; Beretov J; Mackie JD; Beynon S; Simpson AM; Rolph M
Transplant Proc; 1994 Apr; 26(2):704. PubMed ID: 8171616
[No Abstract] [Full Text] [Related]
16. T10B9 action: the effect of anti-T-cell antibody mitogenicity and graft rejection on the first dose cytokine response.
Brown S; Lucas B; Waid T; McKeown W; Tsuchida M; Thompson J
Transplant Proc; 1997; 29(1-2):315-6. PubMed ID: 9123017
[No Abstract] [Full Text] [Related]
17. Immunosuppressive drugs for kidney transplantation.
Halloran PF
N Engl J Med; 2004 Dec; 351(26):2715-29. PubMed ID: 15616206
[No Abstract] [Full Text] [Related]
18. Therapeutic use of the OKT3 anti-T cell monoclonal antibody: mode of action and side effects.
Chatenoud L
Transplant Proc; 1988 Oct; 20(5 Suppl 6):79-83. PubMed ID: 3140452
[No Abstract] [Full Text] [Related]
19. Use of monoclonal antibodies in human transplantation.
Dantal J; Soulillou JP
Curr Opin Immunol; 1991 Oct; 3(5):740-7. PubMed ID: 1755991
[TBL] [Abstract][Full Text] [Related]
20. The clinical application of monoclonal antibody therapies in renal transplantation.
Dhanireddy KK; Xu H; Mannon RB; Hale DA; Kirk AD
Expert Opin Emerg Drugs; 2004 May; 9(1):23-37. PubMed ID: 15155134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
